Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) has been given a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.

Brokers have set a 1 year consensus price objective of $5.00 for the company, according to Zacks. Zacks has also assigned Interpace Diagnostics Group an industry rank of 114 out of 265 based on the ratings given to related companies.

Separately, Maxim Group initiated coverage on shares of Interpace Diagnostics Group in a research note on Tuesday, August 15th. They issued a “buy” rating and a $5.00 target price on the stock.

TRADEMARK VIOLATION WARNING: This piece of content was first published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at

A hedge fund recently bought a new stake in Interpace Diagnostics Group stock. Susquehanna International Group LLP bought a new stake in Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 718,076 shares of the business services provider’s stock, valued at approximately $646,000. Susquehanna International Group LLP owned approximately 3.84% of Interpace Diagnostics Group at the end of the most recent reporting period. 7.58% of the stock is currently owned by institutional investors.

Shares of Interpace Diagnostics Group (IDXG) traded up 1.89% during trading on Friday, hitting $1.62. 1,583,922 shares of the stock traded hands. Interpace Diagnostics Group has a 1-year low of $0.70 and a 1-year high of $19.80. The stock has a 50-day moving average of $1.15 and a 200 day moving average of $1.79. The company’s market cap is $35.91 million.

Interpace Diagnostics Group (NASDAQ:IDXG) last announced its earnings results on Thursday, August 10th. The business services provider reported ($0.65) earnings per share for the quarter. The company had revenue of $3.86 million during the quarter. Interpace Diagnostics Group had a negative net margin of 37.08% and a negative return on equity of 32.06%.

About Interpace Diagnostics Group

Interpace Diagnostics Group, Inc, formerly PDI, Inc, is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management.

Get a free copy of the Zacks research report on Interpace Diagnostics Group (IDXG)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Interpace Diagnostics Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group Inc. and related companies with's FREE daily email newsletter.